On March 25, the National Medical Products Administration (NMPA) and National Health Commission (NHC) officially published the 2025 edition of the Chinese Pharmacopoeia. This new edition contains both traditional Chinese medicines and Western medicines and was reviewed and approved by the 12th Pharmacopoeia Commission Executive Committee of the NMPA in accordance with the Drug Administration Law. The NMPA suggested that the holders of marketing authorizations (MAHs), pharmaceutical manufacturers, and other applicants for drug registration should begin their preparatory work on implementing the 2025 Pharmacopoeia version. Interested parties are encouraged to report issues that occur during the execution process to the Chinese Pharmacopoeia Commission, and all stakeholders should work together to improve the standards for quality and quality controls of drugs.
Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with regulatory and business development issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.